How India Exports Oseltamivir to the World

Oseltamivir, marketed under the brand name Tamiflu, received its initial FDA approval in October 1999 for the treatment of influenza. The first generic version was approved in August 2016. As of March 2026, multiple Abbreviated New Drug Applications (ANDAs) for oseltamivir have been approved, reflecting a competitive generic market. The United States remains the primary destination for Indian oseltamivir exports, accounting for 59.0% of total exports. This robust demand underscores the importance of compliance with FDA regulations, including adherence to Current Good Manufacturing Practices (cGMP) and timely reporting of adverse events.

The European Medicines Agency (EMA) granted marketing authorization for oseltamivir in June 2002. (ema.europa.eu) In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and monitoring of oseltamivir. Manufacturers exporting to these regions must comply with the EU's Good Manufacturing Practice (GMP) guidelines, ensuring product quality and safety. Regular inspections and adherence to pharmacovigilance requirements are essential for maintaining market access.

Oseltamivir is included in the 23rd edition of the WHO Model List of Essential Medicines, published in July 2023. (who.int) This inclusion highlights its significance in global health. The WHO Prequalification Programme has prequalified oseltamivir phosphate, indicating compliance with international quality standards. (extranet.who.int) Manufacturers must ensure that their products meet the specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP).

In India, oseltamivir is classified under Schedule H1 of the Drugs and Cosmetics Rules, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) has not imposed a ceiling price on oseltamivir, allowing market-driven pricing. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for oseltamivir shipments, ensuring compliance with export regulations.

The primary patents for oseltamivir, originally held by Gilead Sciences and licensed to Roche, expired in 2016. (wipo.int) This expiration has led to increased generic competition, with numerous manufacturers entering the market. Indian exporters have capitalized on this opportunity, with 118 active exporters and a total export value of $122.6 million USD.

In June 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of oseltamivir, underscoring its continued importance in influenza treatment. (who.int) In September 2025, the EMA issued updated guidelines on the use of antiviral agents, including oseltamivir, in response to emerging influenza strains, emphasizing the need for ongoing pharmacovigilance. (ema.europa.eu) In November 2025, the NPPA conducted a review of antiviral drug pricing, including oseltamivir, to ensure affordability and accessibility during the influenza season. In January 2026, the CDSCO issued a notification requiring enhanced reporting of adverse drug reactions for oseltamivir, aiming to strengthen patient safety measures. In March 2026, the DGFT streamlined the export NOC process for pharmaceuticals, including oseltamivir, to facilitate timely international shipments.

Oseltamivir, an antiviral medication, relies on specific Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) for its production. A significant portion of these KSMs are sourced from China, which dominates 70–80% of the global KSM supply and 60–70% of the global intermediate supply. This heavy reliance on a single country for critical raw materials introduces substantial supply chain vulnerabilities.

Recent disruptions have highlighted these risks. In February 2026, military escalations in the Middle East led to the closure of the Strait of Hormuz, a vital shipping route. This event caused immediate disruptions in the transportation of petrochemicals and other essential materials, underscoring the fragility of supply chains dependent on specific geographic regions. Such geopolitical events can have cascading effects on the availability of KSMs necessary for Oseltamivir production.

Our proprietary trade data from 2022 to 2026 indicates that the top five Indian exporters of Oseltamivir account for 69.7% of total exports, with NATCO PHARMA LIMITED alone contributing 18.0%. This high concentration among a few suppliers poses a significant risk; any operational or regulatory issues affecting these key players could disrupt the global supply of Oseltamivir.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at reducing dependency on imports for critical pharmaceutical ingredients. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and 6-APA, which are crucial for antibiotic production. While this initiative is a positive step, its impact on diversifying Oseltamivir's supply chain remains to be seen.

The closure of the Strait of Hormuz in February 2026 due to military actions significantly disrupted global shipping routes, affecting the transportation of essential raw materials. Additionally, ongoing tensions in the Red Sea region have further complicated maritime logistics, leading to delays and increased costs. These geopolitical events underscore the vulnerability of supply chains reliant on specific shipping lanes.

Furthermore, the U.S. Food and Drug Administration (FDA) has highlighted the risks associated with quality issues in API manufacturing. In February 2025, the FDA issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practices (cGMP), emphasizing the need for stringent quality controls to prevent supply disruptions.

• Diversify Raw Material Sources: Invest in alternative sources for KSMs and APIs to reduce dependency on single-country suppliers, thereby enhancing supply chain resilience.

• Strengthen Supplier Audits: Implement rigorous and regular audits of suppliers to ensure compliance with cGMP standards, minimizing the risk of quality-related disruptions.

• Develop Contingency Plans: Establish comprehensive contingency strategies to address potential geopolitical and logistical disruptions, ensuring continuity in Oseltamivir production and distribution.

• Enhance Domestic Production: Encourage and support domestic manufacturing of critical pharmaceutical ingredients through incentives and infrastructure development to reduce reliance on imports.

• Monitor Regulatory Compliance: Stay informed about regulatory changes and compliance requirements in key manufacturing regions to proactively address potential issues that could impact the supply chain.

RISK_LEVEL: HIGH